45 results about "Antiallergic drugs" patented technology

A medicament for the preventive and / or therapeutic treatment of allergic diseases and / or endometriosis and / or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

The invention discloses an antiallergic drug sustained release suspension and a preparation method of the suspension. The suspension is prepared from drug-containing particles and a slightly neutral or alkaline suspension matrix, wherein each drug-containing particle respectively comprises a drug-containing core, an isolating coating and a sustained release coating from inside to outside, the drug-containing core comprises a drug, insoluble cation exchange resin, an alkaline soluble polymer and an adhesive, the isolating coating comprises an insoluble polymer, an alkaline soluble polymer, an acid-soluble polymer, a plasticizer and an antisticking agent, the sustained release coating comprises an insoluble polymer, an acid-soluble polymer, a plasticizer and an antisticking agent, and the suspension matrix comprises an alkaline modifier, an acid-soluble polymer, a thickener, a lubricant, a matrix and the like. According to the suspension, the purpose of stabilizing blood concentration by controlling the drug to be released in the gastrointestinal tract through the ion exchange resin, the alkaline soluble polymer and the sustained release coating.

The invention provides a rupatadine fumarate compound which has dual effects of antihistamine and antagonistic platelet activating factor (PAF). According to the research, allergy and inflammatory diseases are multi-factor complex processes caused by generation and release of various different media; histamine is the most inflammatory medium appearing in allergy early symptom, and the disease symptoms including sneezing, rhinocnesmus, tearing, running nose, skin itch, wheal and the like are mostly caused by histamine H1 receptor. And PAF also can cause bronchial constriction and increased permeability of the vessel, so that running nose, nasal congestion, wheal and itch are caused; meanwhile, the PAF is also a main cause of asthma. The antiallergic drug which is clinically used only has an antihistamine activity effect, but does not have a PAF antagonistic effect.

The invention provides a desloratadine citrate disodium oral liquid preparation as well as a preparation method and an application thereof. The oral liquid preparation of the invention comprises desloratadine citrate disodium and pharmaceutically acceptable auxiliary materials, wherein the concentration of the desloratadine citrate disodium in the oral liquid preparation is 0.01-1.0% (w / v), and the pH is 2.0-8.0; and the desloratadine citrate disodium oral liquid preparation comprises an oral solution, a syrup or an oral drip. The desloratadine citrate disodium oral liquid preparation mainly fills the market blank of children antiallergic drugs in the age of six to eleventh months, guarantees the safety of the children medication, and can also meet the requirements of patients with different age groups.

The invention relates to a construction method of recombinant HEK (human embryonic kidney) 293 cells highly expressing H3R (histamine receptor 3). The recombinant cells are constructed by using HEK 293 cells as host cells, and an exogenous expression vector transfecting the host cells is an expression vector comprising an H3R full length gene. The expression vector comprising the H3R full length gene is pEZ-M02 and is an enkaryotic expression vector. The recombinant HEK293-H3R cells highly expressing H3R are applied in screening antiallergic drugs. The construction method comprises extracting an enkaryotic expression vector, pEZ-M02 / H1R plasmid, transfecting the HEK293 cells with the pEZ-M02 / H1R plasmid, screening by utilizing G418 to obtain a genetic engineering cell line HEK293-H3R highly expressing the full length H1R, and confirming that the cell line can improve the expression of the full length H3R by 12 times.

The invention discloses red algae oligosaccharide and a preparation method and application thereof and relates to red algae polysaccharide. Red algae oligosaccharide is red algae polysaccharide of 2-150kDa in molecular weight and is powdery. The preparation method includes: preparing red algae polysaccharide into a polysaccharide solution, cooling after reaction, adding vitamin C for reaction, removing residual vitamin C, adding anhydrous alcohol for precipitating, and drying to obtain red algae oligosaccharide. Red algae oligosaccharide can be applied in preparing antiallergic drug. Accordingto production needs, powdery red algae oligosaccharide can be obtained by utilizing pressure and vitamin C to compositely degrade red algae polysaccharide, and molecular weight is 2-150kDa. Red algaeoligosaccharide obtained by degradation through the method is low in viscosity, high in solubility and strong in antiallergic effect. The preparation method has the advantages of simple equipment andprocess, low cost and easiness in production and application.

The invention relates to a construction method of recombinant HEK (human embryonic kidney) 293 cells highly expressing H1R (histamine receptor 1). The construction method comprises constructing an eukaryotic expression vector pEGFP-N1-H1R for a full length H1R gene by utilizing an eukaryotic expression vector pEGFP-N1, transfecting HEK293 cells with the eukaryotic expression vector pEGFP-N1-H1R, and confirming that the cell line can improve the expression of the full length H1R by 2.58 times. The recombinant HEK293-H1R cells highly expressing H1R is applied in screening antiallergic drugs.

The invention discloses application of phenolic compounds. The phenolic compounds are shown in the formulas (I)-(III). The phenolic compounds are used for preparing anti-allergic drugs. Through research, it is found that the three phenolic compounds have strong inhibition effects on degranulation of mast cells, and can be used for preparing anti-allergic drugs, especially anti-food-allergy drugs;through fermentation of deep-sea fungi, namely penicillium chrysanthum which has rich sources, the three substances with strong anti allergic activity are obtained at the same time, compared with directional synthesis during which a variety of by-products are produced, the preparation method is more suitable for industrial production and natural resources are rationally utilized.

The invention discloses a simple extraction method of coumarin compounds in angelica dahurica. Angelica dahurica is extracted through methanol; an extractive mainly comprises coumarin compounds, suchas imperatorin and isoimperatorin; an antagonistic effect on histamine release of human mast cell KU812 caused by compounds 48 / 80 by the angelica dahurica extractive, imperatorin, isoimperatorin and phellopterin is tested. Results show that the extraction technology is simple and effective, and the angelica dahurica extractive, imperatorin, isoimperatorin and phellopterin can effectively antagonize histamine release of the human mast cell KU812 caused by the compounds 48 / 80. The method provides a novel method and idea on the development of novel antiallergic drugs.

A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect.

The invention discloses an antibacterial and hypoallergenic adult paper diaper and a preparation method thereof. The diapers are sequentially superimposed with a skin-friendly layer, a liquid instant absorption layer and a leak-proof water-proof layer, which are prepared by hot pressing; the skin-friendly layer is made of natural antibacterial materials chitosan and antibacterial drugs combined with inorganic materials, and adopts electrospinning technology The preparation of non-woven fabrics has a high specific surface area and good absorption. The release of antibacterial drugs loaded in inorganic materials can effectively inhibit bacteria and reduce bacterial growth; the absorbent fiber non-woven fabric is used in the liquid instant absorption layer, and at the same time Adding water-absorbing polymers and nano-activated carbon particles to form multiple barriers, not only has the function of air permeability and high water absorption, but also has the characteristics of natural antibacterial and deodorizing. When the ambient temperature is high, moisture and heat are easy to pass through. It is not easy to produce heat and diaper rash; at the same time, the addition of antibacterial and anti-allergic drugs can reduce the growth of bacteria, do not irritate the user's skin, and improve comfort and safety.

The invention provides a rupatadine fumarate compound which has dual effects of antihistamine and antagonistic platelet activating factor (PAF). According to the research, allergy and inflammatory diseases are multi-factor complex processes caused by generation and release of various different media; histamine is the most inflammatory medium appearing in allergy early symptom, and the disease symptoms including sneezing, rhinocnesmus, tearing, running nose, skin itch, wheal and the like are mostly caused by histamine H1 receptor. And PAF also can cause bronchial constriction and increased permeability of the vessel, so that running nose, nasal congestion, wheal and itch are caused; meanwhile, the PAF is also a main cause of asthma. The antiallergic drug which is clinically used only has an antihistamine activity effect, but does not have a PAF antagonistic effect.

The invention provides an antiallergic soap-based shower gel which is prepared from the following components in 100 parts by weight: 12-20 parts of fatty acid, 2-5 parts of potassium hydroxide, 10-15parts of a co-surfactant, 3-8 parts of a skin feel conditioner, 1-3 parts of a viscosity modifier, 1-3 parts of diphenhydramine hydrochloride, 2-8 parts of menthol, 0-0.2 part of isopropyl methylphenol and the balance of deionized water or distilled water. The antiallergic soap-based shower gel provided by the invention is added with an appropriate amount of antiallergic drug diphenhydramine hydrochloride and antibacterial drug isopropyl methylphenol, is combined with menthol to prevent mosquito bites, eczema, sudamen and other skin problems, is used for cleaning skin surface to rapidly play roles of cooling, relieving itching, alleviating pain and sterilizing, is particularly suitable for use in summer, and has no irritation; the preparation method provided by the invention has simple andeasily realizable process and relatively low cost; and the remaining raw materials are added after finally cooling to 35-45 DEG C to prevent the remaining raw materials from being affected by a relatively high temperature.

The invention discloses an anthraquinone compound from fungi in deep sea and application of the anthraquinone compound in preparation of antiallergic drugs. The structure of the anthraquinone compoundfrom fungi in deep sea is shown in formula (I), and the anthraquinone compound can be used for preparing the antiallergic drugs.

A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect.

The invention discloses an antiallergic drug sustained release suspension and a preparation method of the suspension. The suspension is prepared from drug-containing particles and a slightly neutral or alkaline suspension matrix, wherein each drug-containing particle respectively comprises a drug-containing core, an isolating coating and a sustained release coating from inside to outside, the drug-containing core comprises a drug, insoluble cation exchange resin, an alkaline soluble polymer and an adhesive, the isolating coating comprises an insoluble polymer, an alkaline soluble polymer, an acid-soluble polymer, a plasticizer and an antisticking agent, the sustained release coating comprises an insoluble polymer, an acid-soluble polymer, a plasticizer and an antisticking agent, and the suspension matrix comprises an alkaline modifier, an acid-soluble polymer, a thickener, a lubricant, a matrix and the like. According to the suspension, the purpose of stabilizing blood concentration by controlling the drug to be released in the gastrointestinal tract through the ion exchange resin, the alkaline soluble polymer and the sustained release coating.

The invention belongs to the field of research and development of medicines and health products, and particularly relates to an application of NADH and / or NADPH in antiallergic drugs and / or antiallergic health products. The present invention provides the application of NADH and / or NADPH in the antiallergic drugs and / or the antiallergic health products. In the present invention, NADH / NADPH can be administrated to induce Treg cells to secrete immunosuppressive cytokines IL10, TGF-beta and the like. which can inhibit the immune response of TH2, blood basophilia and tissue mast cells, reduces sIgEsynthesis, and increases sIgG and sIgA synthesis, and alleviates allergy symptoms; can stimulate the allergen-specific TH1 response, produces cytokines IFN-gamma and TGF-gamma, inhibits the immune response of TH2, blood basophilia and tissue mast cells, reduces sIgE synthesis and increases sIgG and sIgA synthesis, and alleviates allergy symptoms. The application solves the technical defects thatthe anti-allergic drugs have some adverse reactions, need repeated medication and allergic recurrence, and provides a long-acting, immunomodulatory natural anti-allergic drug or health care product.

The invention discloses a pure traditional Chinese medicine antiallergic drug and a preparing method thereof and relates to the technical field of traditional Chinese medicine. The drug is prepared from, by weight, 10-30 g of divaricate saposhnikovia root, 10-40 g of flos chrysanthemi, 10-30 g of cassia twig, 10-40 g of radix lithospermi, 5-35 g of fructus kochiae, 5-25 g of radix sanguisorbae and 10-20 g of licorice root. The preparing process is convenient and environment-friendly, no additive is adopted, and the antiallergic drug can take effect quickly, is pure traditional Chinese medicine, and is convenient to take and free of side effect.

The invention relates to an animal model for bronchial allergic cough induced by histamine and citric acid. The animal model for the histamine sensitized and citric acid induced cough is designed in combination with the onset characteristics and rules of bronchial allergic cough, the animal model has a large therapeutic window, both traditional antiallergic drugs and antitussive drugs can play a good therapeutic role, and medication conditions of the animal model are consistent with medication conditions of clinically related patients. Therefore, the animal model can be used for evaluating and screening related drugs.

The invention discloses an antiallergic drug. The antiallergic drug is prepared from the following substances by weight: 10 to 20 parts of schizonepeta, 7 to 16 parts of fructus cnidii, 5 to 9 parts of rhizoma smilacis glabrae, 2 to 5 parts of cicada slough, 1 to 7 parts of radix angelicae, 15 to 18 parts of mint, 10 to 23 parts of frankincense and 3 to 7 parts of a sweetening agent. According to the antiallergic drug provided by the invention, antibacterial, antipyretic and anti-inflammation effects of the schizonepeta are used, and then the Chinese herba preparations such as fructus cnidii, rhizoma smilacis glabrae, cicada slough, radix angelicae, mint and frankincense are cooperatively used, so that the drug has a good antiallergic effect and can be used for curing allergic symptoms caused by food and contact; and besides, the antiallergic drug can also be applicable to chronic measles, skin tinea and the like, and has an obvious taking effect. No chemical hazardous substances are added in the preparation process, no side effect is generated after the drug is taken, and the antiallergic drug is simple in production technology, relatively low in cost and suitable for popularization and application.

The present invention provides a novel target protein and a gene for drug discovery, and a means that enables development of a novel pharmaceutical agent by using the same. More particularly, the present invention provides CARP and genes thereof; screening methods for drugs (e.g., antiallergic drugs); a regulator of diseases (e.g., allergic diseases); a drug derivative production method; a complex comprising a drug and CARP, and a production method thereof; kits comprising a drug or a salt thereof; determination methods for the onset or risk of onset of a specified disease, determination methods for susceptibility to a drug, and determination kits used for said methods, and the like.

The invention discloses the application of coyne in the preparation of anti-allergic drugs, by comparing the degranulation of KU812 cells, the degree of swelling of the toes, the degree of Evans blue exudation of the toes, HE staining of foot skin tissue sections, and the release of serum histamine To evaluate the drug group to be tested, the normal saline control group and the normal control group, to evaluate the therapeutic effect of the drug on allergic diseases, and to determine that coyne can be used in the preparation of anti-allergic drugs. Coin can effectively alleviate the symptoms of local and systemic allergic reactions in mice; reduce mast cell degranulation and significantly improve the symptoms caused by allergic reactions.

The invention discloses an application of 4-methylumbelliferone in preparation of antiallergic drugs, the chemical structural formula of the 4-methylumbelliferone is shown in the specification, in an in-vitro experiment, through an in-vitro research method for comparing RBL-2H3 and BMMCs degranulation and an in-vivo experiment research method for a passive sensitization model PCA and an active systemic sensitization model ASA, the application of 4-methylumbelliferone in preparation of antiallergic drugs is realized, and the application of 4-methylumbelliferone in preparation of antiallergic drugs is realized. It is determined that the 4-methylumbelliferone can relieve the degranulation effect of IgE-mediated mast cells and effectively relieve local and systemic anaphylactic reaction symptoms of an organism.

The invention discloses application of Licochalcone A in preparation of an antiallergic drug. A to-be-detected drug group, a normal saline control group and a normal control group are evaluated by comparing a mastocyte degranulation degree, a mouse toe swelling degree, a toe Evans blue exudation degree and a body temperature lowering degree, so that the treatment effect of the drug for allergic diseases is evaluated; a result determines that the Licochalcone A can be used for preparing the antiallergic drug. The Licochalcone A can effectively relieve local and systemic anaphylactic reaction symptoms of mice. Mastocyte degranulation is reduced, and symptoms caused by allergy are remarkably eliminated.

The invention discloses halogenated diarylurea compounds and application thereof in preparation of an antiallergic drug, and discloses for the first time that the halogenated diarylurea compounds caneffectively antagonize beta-aminohexylglycosidase release and histamine release of human basophilic granulocyte KU812 caused by C48 / 80, so as to inhibit anaphylactoid reaction. Therefore, when the halogenated diarylurea compounds are used as an anti-allergic preparation, the types of anti-allergic medicines are enriched, and more possible treatment schemes are provided for clinical anti-allergic treatment.

The invention discloses penicillium commune T3-1, fermentation compounds thereof, an extraction and purification method and an antiallergic application. Penicillium commune T3-1 is preserved in CCTCC (China Center for Type Culture Collection) in Wuhan University in Wuhan, China on March 15th, 2017, and the preservation number is CCTCC NO: M 2017123. The structures of the compounds obtained from Penicillium commune T3-1 through fermentation and extraction are shown as formulae (I) and (II) in the specification. Experiments discover that the compounds have higher antiallergic activity and can be used for preparing and developing antiallergic drugs. New compound sources are provided for research and development of the antiallergic drugs, and the compounds have great significance for development of marine drugs in China, can further promote effective application of deep-sea biological resources and have good application prospect.

The present invention provides an antiallergic agent comprising, as an active ingredient, at least one of a tomato extract, tomato pericarp, naringenin chalcone or its derivatives, tricaffeoylquinic acid or its derivatives and dicaffeoylsuccinylquinic acid or its derivatives; a histamine-release inhibitor or a leukotriene-release inhibitor; and a medicament, food, drink or cosmetic comprising the antiallergic agent, the histamine-release inhibitor or the leukotriene-release inhibitor mentioned above; and a method for producing an antiallergic agent comprising extracting raw material tomato with a solvent.

The invention discloses antiallergic drug coating composition. The antiallergic drug coating composition is characterized by comprising antiallergic drug particles and polymer A particles, wherein the polymer A is selected from sodium alginate or chitosan, and the antiallergic drug particles account for 15%-20% of the total mass. The drug composition is applied to the inside of the paranasal sinus (by spraying or brushing) to form a drug coating, drug ingredients in the coating are released slowly, and long-term fixed-point and quantitative administration to the part of lesion can be realized. The invention further provides a preparation method and an application of the composition.